COVID-19 mAb developers weigh master protocols as they set clinical strategies

Drugmakers developing the first crop of COVID-specific mAbs are facing the question of whether to pursue independent, company-sponsored trials or participate in master protocols that have been successful for repurposed drugs during the pandemic. So far, they’re opting for the independent route.

For Regeneron Pharmaceuticals Inc. (NASDAQ:RGEN) and Eli Lilly and Co. (NYSE:LLY), the two companies with the most advanced neutralizing antibodies, the choice was primarily a matter of timing. ...